Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis?

Arthritis and Rheumatism

Volumn 62, Issue 3, 2010, Pages 639-642

  Hahn, Bevra H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; AUTOANTIBODY; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY BLOOD LEVEL; ATHEROSCLEROSIS; AUTOIMMUNITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; AUTOANTIBODIES; CHOLESTEROL, HDL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 77649155877     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27298     Document Type: Editorial

References (26)

1. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75.
2. O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54.
3. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 1993;86:447-58.
4. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.
5. Hahn BH, Grossman J, Ansell BJ, Skaggs BH, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008;10:213-20.
6. Ortiz-Munoz G, Houard X, Martin-Ventura JL, Ishida BY, Loyau S, Rossignol P, et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009;23:3129-39.
7. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Draber TR. HDL as a protective factor against coronary artery disease: the Framingham Study. Am J Med 1977;62:707-14.
8. Rosenson RS. Lipids and atherosclerosis. UpToDate, searched 09/20/09. URL: www.UpToDate.com.
9. Von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr Opin Lipidol 2009;20:197-205.
10. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007;19:633-9.
11. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, et al. Hemoglobin and its scavenger protein haptoglobin associate with ApoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009;284:18292-301.
12. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54: 2541-9.
13. McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-37.
14. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules-Creactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1) and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005;25:582-91.
15. Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:227-39.
16. Vuilleumiere N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 2008;115:25-33.
17. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:26-31.
18. Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:137-46.
19. Nikpour M, Gladman DD, Ibanez D, Bruce IN, Burns IT, Urowitz MB. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol 2009;36:288-94.
20. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
21. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
22. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2220-7.
23. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008;35:1300-6.
24. -/- mice. J Am Coll Cardiol 2007;50:2313-8.
25. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009;120:417-26.
26. Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E. The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 2005;1051:442-54.